Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

Thorax

Volumn 66, Issue 3, 2011, Pages 259-260

  Alghisi, Federico ^a   Palma, Paolo ^a   Montemitro, Enza ^a   Bernardi, Stefania ^a   Pontrelli, Giuseppe ^a   Rossi, Paolo ^a   Lucidi, Vincenzina ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

CHILD HEALTH; CHILL; CYSTIC FIBROSIS; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; INFLUENZA A (H1N1); INJECTION SITE PAIN; INJECTION SITE SWELLING; LETTER; MYALGIA; PANDEMIC INFLUENZA; PRIORITY JOURNAL;

EID: 79951951238     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.156018     Document Type: Letter

References (5)

1. Johansen HK, Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992;47:109-11.
2. Ortiz JR, Neuzil KM, Victor JC, et al. Influenza-associated cystic fibrosis pulmonary exacerbations. Chest 2010;137:852-60.
3. Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2009;(4):CD001753. doi:10.1002/14651858.
4. France MW, Tai S, Masel PJ, et al. The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis. BMC Pulm Med 2010;10:8.
5. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, 1997. http://www.ema.europa. eu/pdfs/human/bwp/021496en.pdf (accessed 28 Jan 2010).